Medline (NASDAQ:MDLN) Given Average Recommendation of “Moderate Buy” by Analysts

Medline (NASDAQ:MDLN) has earned a consensus recommendation of “Moderate Buy” from the twenty-nine ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $50.5385.

Several equities analysts have recently issued reports on the company. Citigroup lowered their price target on Medline from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Wells Fargo & Company lifted their price target on Medline from $42.00 to $47.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Morgan Stanley lifted their price target on Medline from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Royal Bank Of Canada lifted their price target on Medline from $47.00 to $53.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, BMO Capital Markets lifted their price target on Medline from $45.00 to $54.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Recent insider buying is helping sentiment, with Principal Accounting Officer Jessi L. Corcoran purchasing 5,000 shares at $34.15, signaling confidence from management.
• Positive Sentiment: Investors appear to be digesting Medline’s recently completed debt refinancing and new term loan structure as a cleaner balance sheet setup that reduces near-term financing uncertainty.
• Positive Sentiment: The large secondary offering was sold by existing shareholders rather than Medline issuing new shares, which may ease concerns about direct company-level dilution.
• Neutral Sentiment: Medline’s presentation at the Goldman Sachs healthcare conference kept the stock in focus, but the provided details did not include a major new operating catalyst.
• Neutral Sentiment: Management’s recent investor and analyst attention may be reinforcing the view that the company remains fundamentally solid after its strong recent earnings report.
• Negative Sentiment: Fresh securities-fraud investigation headlines could pressure the shares by raising legal and disclosure-risk concerns, even though no wrongdoing has been established.
• Negative Sentiment: Some analyst commentary has turned more cautious, including a recent Barclays target cut to $45 from $50, citing margin pressure concerns.

Insider Activity at Medline

In other Medline news, insider Jessi L. Corcoran acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were bought at an average cost of $34.15 per share, with a total value of $170,750.00. Following the completion of the transaction, the insider directly owned 5,000 shares of the company’s stock, valued at approximately $170,750. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.81% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medline

Several institutional investors have recently modified their holdings of MDLN. Sound Income Strategies LLC purchased a new stake in shares of Medline during the fourth quarter valued at $25,000. Entrust Financial LLC purchased a new stake in shares of Medline during the fourth quarter valued at $26,000. NBC Securities Inc. purchased a new stake in shares of Medline during the fourth quarter valued at $28,000. Whipplewood Advisors LLC purchased a new stake in shares of Medline during the first quarter valued at $30,000. Finally, Global Retirement Partners LLC purchased a new stake in shares of Medline during the fourth quarter valued at $31,000.

Medline Price Performance

MDLN opened at $36.54 on Thursday. The stock has a 50-day moving average of $41.06. The company has a current ratio of 4.41, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65. The stock has a market cap of $48.00 billion and a price-to-earnings ratio of 114.19. Medline has a 1 year low of $32.81 and a 1 year high of $50.88.

Medline (NASDAQ:MDLN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.04. The company had revenue of $7.35 billion during the quarter. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Medline will post 1.51 EPS for the current year.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.